Medical Developments International (ASX:MVP) has just announced that Penthrox has been approved for sale in Germany.
The pain relief medication saw recent approvals in Sweden, Norway, Croatia and Poland. Finland is expected soon.
The CEO says with a population of almost 83 million people in Germany it is the largest spender of healthcare in Europe.
Germany is also the largest user of opioids in Europe. Penthrox is a non-opioid pain relief self-administered with an inhaler.
It has been used safely and effectively for over 40 years in Australia.
Clinical data is still being gathered to submit a new drug application to the Food and Drug Administration in the US.
Shares in Medical Developments International (ASX:MVP) are up 3.28 per cent to $7.24